-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2141 Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes

Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I
Hematology Disease Topics & Pathways:
Treatment Considerations, Biological therapies, Transplantation (Allogeneic and Autologous)
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Muhammad Umair Mushtaq1,2,3, Amir Kasaeian1,3*, Muhammad Kashif Amin, MD1,2,3*, Aqeeb Ur Rehman, MD1*, Naghmeh Khavandgar1,3*, Hediyeh Alemi1,3*, Sibgha Gull Chaudhary, MD1,2,3*, Iqra Anwar, MBBS1,3*, Matthew McGuirk1,3*, Haitham Abdelhakim, MD3,4, Anurag K. Singh, MD1,2,3, Mehdi Hamadani, MD3,5, Joseph P. McGuirk, DO1,2,3 and Moazzam Shahzad, MD3,6

1Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
2US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
3Mikael Rayaan Foundation Global Health Consortium, Kansas City, KS
4Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS
5Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
6Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL

Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for patients with acute leukemia (AL) and myelodysplastic syndromes (MDS). The intensity of the conditioning regimen before transplantation, myeloablative versus reduced intensity or non-myeloablative conditioning, can significantly impact post-transplant outcomes. We aimed to investigate the impact of conditioning intensity on post-transplant outcomes in AL/MDS patients undergoing related donor allo-HCT with post-transplant cyclophosphamide (PT-Cy)-based graft-versus-host disease (GVHD) prophylaxis.

Methods: A retrospective multicenter analysis was conducted, including allo-HCT patients in the publicly available Center for International Blood and Marrow Transplant (CIBMTR) registry from 2012 to 2017 using P5737 data by Ustun et al. We examined the impact of conditioning intensity on post-transplant outcomes, including overall survival (OS), disease-free survival (DFS), relapse, non-relapse mortality (NRM), grade 2-4 acute GVHD (aGVHD), chronic GVHD (cGvHD), and GvHD-free relapse-free survival (GRFS). Patient-, disease- and transplant-related factors were compared between groups using the Chi-square test for categorical variables and the Wilcoxon two-sample test for continuous variables. The median follow-up duration was estimated using the reverse Kaplan-Meier method. Cox proportional hazards regression was used for outcomes, including OS, DFS, GRFS, aGVHD, cGVHD, relapse, and NRM. The hazard ratios (HR) with 95% confidence intervals (CI) were calculated. Variables with p-values <0.2 in univariable analysis and the clinically relevant variables were included in the multivariable models. A significance level of 0.05 was used throughout. Statistical analyses were conducted using Stata version 18.

Results: We included 865 allo-HCT patients, 370 (43%) of whom underwent myeloablative conditioning (MAC), while 495 (57%) had reduced intensity or non-myeloablative conditioning (RIC/NMAC). The median age at the time of transplant was 46.6 years in the myeloablative cohort and 62.5 years in the RIC/NMAC cohort (p<0.001). Fifty-nine percent (n=514) were men. Ethnicities were Caucasian (64%), African American (18%), Hispanic (10%), and Asian and others (8%). The primary disorders included acute myeloid leukemia (54%), MDS (26%), and acute lymphoblastic leukemia (20%). Patients received either haploidentical (haplo, 64%) or matched sibling donor (MSD, 36%) transplants. Graft sources were peripheral blood stem cells (65%) and bone marrow (35%). All patients received PT-Cy-based GVHD prophylaxis. Fifty percent of patients had a Karnofsky performance score of 90% or higher, and 20% had a comorbidity index of 0. The median follow-up time was 3.61 (3.14-3.88) years. Univariate regression analyses revealed that patients who underwent RIC/NMAC had a significantly inferior OS (Median 1.88 years RIC/NMAC vs. 5.07 years MAC; HR 1.38, 95% CI 1.14-1.68, p=0.001) and DFS (Median 0.67 years RIC/NAMC vs. 2.05 years MAC; OR 1.57, 95% CI 1.31-1.87, p<0.001) and higher risk of relapse (51% RIC/NMAC vs. 31% MAC; HR 1.95, 95% CI 1.56-2.43, p<0.001), while a lower risk of grade II-IV aGvHD (33% RIC/NMAC vs. 40% MAC; HR 0.76, 95% CI 0.60-0.94, p=0.014) was observed with RIC/NMAC. Conditioning intensity did not impact GRFS, NRM, and cGvHD. In multivariate regression analyses, RIC/NMA was associated with a significantly higher risk of relapse (HR 1.60, 95% CI 1.01-2.54, p=0.045) but did not significantly impact other transplant outcomes.

Conclusion: Our study demonstrates the potential benefits of myeloablative conditioning in reducing the relapse rate after haploidentical and matched sibling donor hematopoietic cell transplantation with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and should be considered in eligible patients.

Disclosures: Mushtaq: Iovance Biotherapeutics: Research Funding. Abdelhakim: Iovance Biotherapeutics: Research Funding. Hamadani: Myeloid Therapeutics: Speakers Bureau; Forte Biosciences: Consultancy; Genmab: Consultancy; BeiGene: Speakers Bureau; CRISPR: Speakers Bureau; Byondis: Consultancy; Genentech: Speakers Bureau; DMC, Inc: Speakers Bureau; CRISPR: Consultancy; Autolus: Consultancy; Takeda: Research Funding; Kite Pharma: Consultancy, Speakers Bureau; ADC Therapeutics: Consultancy, Research Funding, Speakers Bureau; Spectrum Pharmaceuticals: Research Funding; AstraZeneca: Speakers Bureau; Sanofi Genzyme: Speakers Bureau; AbbVie: Consultancy; BMS: Consultancy; Caribou: Consultancy; Allovir: Consultancy; Omeros: Consultancy; Astellas Pharma: Research Funding. McGuirk: Legend biotech: Consultancy; Autolus: Consultancy; Envision: Consultancy; Allo Vir: Consultancy; Caribou bio: Consultancy; Sana technologies: Consultancy; Novartis: Consultancy; NEKTAR therapeutics: Consultancy; CRISPR therapeutics: Consultancy; Kite: Consultancy; BMS: Consultancy.

*signifies non-member of ASH